Study of Ribociclib and Everolimus in HGG and DIPG
Status:
Not yet recruiting
Trial end date:
2033-08-15
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the efficacy of the study drugs ribociclib and
everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade
glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR)
that these drugs target.
The main question the study aims to answer is whether the combination of ribociclib and
everolimus can prolong the life of patients diagnosed with HGG, including DIPG.